LONDON–(BUSINESS WIRE)– DB ETC PLC Dated: 16 September 2026 COMPANY ANNOUNCEMENT Immediate Release 16 September 2026 DB ETC plc (the Issuer) Law 1991 (as amended) with registered number 103781) Re: Issuance of ETC Securities Announcement The Issuer has agreed to issue ETC Securities for the following Series as set out in the table below. Series Tranche Number of Securities to be issued Trade Date Settlement Date ISIN: Series 04 – Xtrackers Physical Silver EUR Hedged ETC 456 4,000 14 Septem
Month: September 2026
LONDON–(BUSINESS WIRE)– Consort Healthcare (Birmingham) Funding GBP398,680,000 1.972per cent Index Linked Guaranteed Secured Bonds due 2044 ISSUE NAME. Our Ref. B24317 ISIN Code. XS0257525112 INTEREST AMT PER DENOM. CURRENCY CODE. GBP DAY BASIS. Actual/Actual ISMA (A006) NUM OF DAYS. 183 INTEREST RATE. 0 PCT VALUE DATE. 30/09/2026 INTEREST PERIOD. 31/03/2026 TO 30/09/2026 GBP 1,000.00 IS GBP 12.88 POOL FACTOR. 0.6215490
ROME–(BUSINESS WIRE)– #connectedness–The Mediterranean Network for Haemoglobinopathies (MNfH) was recently launched at Palazzo Wedekind in Rome, bringing together leading clinicians and patient representatives from Cyprus, Greece, and Italy, with the Thalassaemia International Federation (TIF). Supported by Avanzanite Bioscience as Founding Sponsor, the independent regional platform will connect expertise across borders, strengthen the patient voice, and turn shared knowledge into practical initiatives that
ATLANTA–(BUSINESS WIRE)–NCR Atleos Corporation (NYSE: NATL) (“Atleos”), a leader in expanding self-service financial access for financial institutions, retailers and consumers, today announced that Bank Pekao S.A., one of the largest financial institutions in Central and Eastern Europe, has selected the Atleos Authentic™ payment switching platform as part of its card payment processing infrastructure modernization strategy. Under the agreement, Atleos will provide its Authentic switch platfor
LONDON–(BUSINESS WIRE)– Consort Healthcare (Mid Yorkshire) Funding GBP214,531,000 2.055per cent Index Linked Guaranteed Secured Bonds due 2041 (incl GBP43,000,000 Variation Bonds) ISSUE NAME. Our Ref. B38689 ISIN Code. XS0307799246 INTEREST AMT PER DENOM. CURRENCY CODE. GBP DAY BASIS. Actual/Actual ISMA (A006) NUM OF DAYS. 183 INTEREST RATE. 0 PCT VALUE DATE. 30/09/2026 INTEREST PERIOD. 31/03/2026 TO 30/09/2026 GBP 1,000.00 IS GBP 11.74 POOL FACTOR. 0.5632330
FRANKFURT AM MAIN, Germany–(BUSINESS WIRE)–Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has received approval in the European Union (EU) / European Economic Area (EEA) for XEOMIN® (incobotulinumtoxinA) for the symptomatic treatment of spasticity associated with pes equinus, a condition in which tight calf muscles cause the foot to point downward, in ambulant and non-ambulant children and adolescents with cerebral palsy (CP) aged 2 to 17 ye
LONDON–(BUSINESS WIRE)– City Of Goteborg Issue of SEK 650,000,000.00 Floating Rate Green Notes due September 2030 Series No GB45 Tranche 1 MTN ISSUE NAME. Our Ref. MU3765 ISIN Code. XS3184154394 TOTAL INTEREST AMT. CURRENCY CODE. SEK DAY BASIS. Actual/360 (A004) NUM OF DAYS. 91 INTEREST RATE. 2.8 PCT VALUE DATE. 18/12/2026 INTEREST PERIOD. 18/09/2026 TO 18/12/2026 SEK 4,600,555.56 POOL FACTOR. N/A
COPENHAGEN, Denmark, September 17, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that Tarja Stenvall has been appointed President and Chief Executive Officer, effective October 15, 2026, succeeding Paul Chaplin whose departure was announced earlier this year.
Tarja Stenvall is a global healthcare executive with over 20 years of leadership experience from Sanofi, AstraZeneca, and Pfizer, combining deep commercial expertise with a proven track record of building and transforming businesses at scale. She has held country, regional, and global roles across specialty care, general medicines, and vaccines, leading organizations of more than 3,000 people and having more than 3 billion euros profit-and-loss responsibility.
Chair of the Board of Directors, Anne Louise Eberhard, said: “Following a comprehensive search, the Board is pleased to appoint Tarja Stenvall as new Chief Executive Officer of Bavarian Nordic. Tarja Stenvall brings a proven ability to scale and lead a global life science business, combining strategic vision with deep experience from global pharma and vaccines industry and passion for improving and protecting lives. Bavarian Nordic is entering the next chapter from a position of strength. We have a clear purpose, and we will continue to scale our unique platform addressing infectious disease and improve the resilience of public health. The Board trusts Tarja to be the right profile to lead Bavarian Nordic. On behalf of the Board, I would also like to express our sincere appreciation to Paul Chaplin for his many years of dedicated leadership and profound impact on Bavarian Nordic. Under his leadership, the company evolved from a research-focused organization into a global vaccines company that today plays an important role in securing public health worldwide.”
Tarja Stenvall said: “The opportunity to join Bavarian Nordic is tremendously exciting. What attracted me to Bavarian Nordic is its unique combination of a strong scientific foundation, a proven global manufacturing and supply chain and commercial platform. The company has built a leading position in vaccines while remaining firmly committed to improving and protecting lives, making this a truly compelling opportunity. Throughout my career in the life sciences and vaccine industry, I have been passionate about translating scientific innovation into meaningful patient impact by building global organizations and delivering long-term value and sustainable growth. I believe the company has a strong foundation for its next phase of growth, and I am excited by the opportunity to expand the global impact of Bavarian Nordic’s vaccines while continuing to strengthen the company’s position as a leading global vaccine company.”
Effective October 15, 2026, the Executive Management of Bavarian Nordic will consist of the following:
- Tarja Stenvall, President & Chief Executive Officer
- Henrik Juuel, EVP & Chief Financial Officer
- Jean-Christophe May, EVP & Chief Commercial Officer
- Russell Thirsk, EVP & Chief Operating Officer
About Tarja Stenvall
Tarja Stenvall is a senior pharmaceutical executive recognized for leading large-scale organizations across Europe, Latin America, and global markets. Throughout a career spanning more than two decades, she has held senior leadership positions at Sanofi, AstraZeneca, and Pfizer, building a reputation for driving sustainable growth, organizational transformation, and improved patient access to innovative medicines and vaccines.
She most recently served as Senior Vice President and Head of Global Franchise for diabetes and cardiovascular diseases at Sanofi, where she oversaw global portfolio strategy and long-term planning for a €10B franchise. Prior to this role, she held several senior leadership positions within Sanofi, including Senior Vice President for Key Markets in General Medicines, Senior Vice President for Europe, and Vice President for Vaccines in Latin America where she secured Sanofi’s largest global private-public partnership. During her tenure with Sanofi, she served as member of the Global Business Unit Leadership Team and the Global Sanofi Sustainability Impact Committee.
Prior to joining Sanofi in 2014, Tarja held various commercial leadership roles with increasing responsibility at AstraZeneca and has also held commercial leadership positions in Pfizer.
Tarja Stenvall holds a degree in Economics from Aalto University (formerly the Helsinki School of Economics and Business Administration) in Finland, and an MBA in International Business from the University of South Carolina in the US.
Images for the press are available on the company’s website:
https://www.bavarian-nordic.com/media/media/ceo.aspx
About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Contact investors:
Anders Hjort, Head of Investor Relations, ahjo@bavarian-nordic.com, Tel. +45 44 74 99 58
Graham Morrell, Gilmartin Group, graham@gilmartinir.com, Tel: +1 781 686 9600
Contact media:
Nicole Seroff, Vice President Corporate Affairs, nise@bavarian-nordic.com, Tel: +45 53 88 06 03
Company Announcement no. 43 / 2026
This announcement contains publication of inside information pursuant to Article 17 of the EU Market Abuse Regulation.
Attachment
Maranello (Italy), September 17, 2026 – Ferrari N.V. (NYSE/EXM: RACE) announces that Ferrari S.p.A., wholly-owned Italian subsidiary of Ferrari N.V., today has signed a partnership agreement with Rakuten Group, Inc., a global technology company, that will be effective from January 1, 2027.
Attachment
VANCOUVER, British Columbia–(BUSINESS WIRE)–Nano One® Materials Corp. (« Nano One » ou la « Société ») (TSX : NANO) (OTCQB : NNOMF) (Francfort : LBMB), une entreprise de technologie de procédés spécialisée dans les matériaux actifs de cathode pour batteries lithium-ion, a annoncé aujourd’hui qu’Alex Holmes, PDG et membre du conseil d’administration, prendra un congé médical temporaire. L’entreprise s’attend à ce que M. Holmes revienne dans les prochains mois. En consultation avec M. Holmes, l